Skip to main content

Eocene Ltd.

corporate_fare Company Profile

Eocene Ltd.

EOCN·NASDAQ·Life Sciences·CIK 0001595353

Eocene Ltd. is a biopharmaceutical company focused on the development of Aramchol, a first-in-class, oral, SCD1 modulator. Historically, the company has focused almost exclusively on developing Aramchol for the treatment of liver diseases and was previously developing Aramchol for primary sclerosing cholangitis, or PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of MASH and liver fibrosis. Eocene Ltd. has recently reinitiated the process of evaluating its strategic options alternatives and its structuring to best optimize its resources to enhance shareholder value and achieve its goals. The company is currently seeking to advance the development of Aramchol for combination therapy for GI oncological indications. In addition, as part of its growth strategy, Eocene Ltd. is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline, specifically targeting GI, cardiometabolic indications and other innovative product candidates that align with its core competences. Aramchol, Eocene Ltd.'s lead product candidate, is a synthetic conjugate of 3-amino cholic acid, a type of modified bile acid, and arachidic acid, a type of saturated fatty acid, which in its non-synthetic forms is naturally occurring. The conjugated molecule acts upon important metabolic pathways, reducing fat accumulation in the liver, improving fatty acid oxidation and regulating the transport of cholesterol. The ability of Aramchol to decrease liver fat content may also reduce the inflammation and fibrosis in the liver and the risk of cardiovascular complications associated with NASH. Pre-clinical studies suggest Aramchol's effect on fibrosis is also direct via collagen production from human hepatic stellate cells. Eocene Ltd. believes that Aramchol's ability to reduce liver fat and liver fibrosis and the safety profile observed to date will enable it to be a treatment for all stages of NASH in patients who are overweight or obese and have pre diabetes or type II diabetes mellitus and prevent the hepatic complications associated therewith. In September 2019, Eocene Ltd. initiated its Phase 3 ARMOR Study to evaluate the efficacy and safety of Aramchol in subjects with NASH and fibrosis.

Eocene Ltd. (NASDAQ:EOCN) is a publicly traded company in the Life Sciences sector.

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$10.31M
Diluted EPS
$2.39
Op. Cash Flow
-$6.32M
Cash & Equivalents
$3.98M
Debt / Equity
0.00×
Shares Outstanding
6.58M sh
Source: 20-F · filed 2026-03-31 · accession 0001493152-26-014182

Short Interest & Short Volume

1.31 days to cover

FINRA reported short interest of 8,397 shares in EOCN as of the October 30, 2026 settlement, a 11.7% increase from the prior period — about 1.3 days to cover at its recent average daily volume. On November 19, 2026, 43.5% of EOCN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)8,397 shares as of October 30, 2026
Change vs prior period▲ 11.7%
Days to cover1.31 at avg daily volume of 6,388
Daily short volume (FINRA facilities)43.5% of 11,445 shares on November 19, 2026
5-day average short volume27.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

EOCN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$1.78 +1.73% today
Market cap
$1.85M
Volume
9.2K (1.0× avg)
3-mo avg 9.3K
Live data · 2026-11-20 23:28 UTC · After hours

show_chartPrice Chart

Loading chart...

feed EOCN - Latest Insights

Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets